Search Results - therapeutics

25 Results Sort By:
Combining recombinant protein and fibrin spray to increase wound healing
Overview A little-appreciated complication of pneumonia in surgical patients is decreased wound healing. We have invented a treatment method that uses fibrin spray as a vehicle to topically deliver one or more chemokines to accelerate wound healing. Advantages of our method include effectiveness, ease of application, and the use of already-approved...
Published: 2/22/2024   |   Inventor(s): Amanda Jamieson, Meredith Crane, Yun Xu
Category(s): Therapeutics
Small-Molecule Inhibitors of the L-1 Endonuclease Domain
Overview Chronic inflammation is a hallmark of a number of age-related diseases, as well as of aging itself. Nuclear element-1 (L1) plays a key role in this inflammatory process. We have developed the first inhibitors of the L-1 endonuclease (EN) domain and the first of any retrotransposon-encoded EN. Our technology sheds light on the regulators that...
Published: 7/25/2023   |   Inventor(s): John Sedivy, Gerwald Jogl, Alexandra D'Ordine
Category(s): Therapeutics
Anti-Cancer Maleimide Derivatives for Use with Immune Checkpoint Blockade
Overview We have invented a cancer treatment that consists of administering an anti-cancer maleimide derivative together with an immune checkpoint blockade. Market Opportunity Globally, colorectal cancer (CRC) ranks third in incidence and second in mortality. The U.S. Food and Drug Administration recently approved the checkpoint inhibitors nivolumab...
Published: 6/7/2023   |   Inventor(s): Wafik El-Deiry, Kelsey Huntington
Category(s): Therapeutics, Oncology
Use of CRTH2 Antagonist to Treat Neuromyelitis Optica and Other Autoimmune Disorders of the Central Nervous System
Overview The detrimental effects of neuroinflammation, especially neuromyelitis optica spectrum disorder (NMOSD), on cognitive performance can include severe vision loss, motor deficits, and cognitive decline. We have invented a method that targets the detrimental effects of neuroinflammation on cognitive performance by using a CRTH2 (chemoattractant...
Published: 6/7/2023   |   Inventor(s): Yu-Wen Huang, Changyong Tang, Wei Qiu, Yaxiong Cui
Category(s): Central Nervous System(CNS), Therapeutics
Covid Prevention and Treatment Using an Integrin Inhibitor
Overview Although several highly effective vaccines against COVID-19 have been developed, the disease remains a threat to public health. We have invented a method of preventing or treating COVID-19 through administration of an integrin inhibitor such as GLPG-0187. Market Opportunity Although several highly effective vaccines against COVID-19 have...
Published: 6/7/2023   |   Inventor(s): Wafik El-Deiry, Kelsey Huntington, Lindsey Carlsen, Olin Liang, Matthias Piesche
Category(s): Therapeutics, Infectious Disease
L1 Inhibitor to Prevent Age-Associated Inflammation and Disease
Overview One hallmark of aging is the accumulation of senescent cells that contribute to sterile inflammation, which underlies many age-associated diseases such as osteoarthritis, cancer, and neurodegeneration. Nuclear element-1 (L1), which represents approximately 17% of the human genome, plays a key role in this process. We are identifying candidates...
Published: 1/21/2023   |   Inventor(s): John Sedivy, Gerwald Jogl, Alexandra D'Ordine
Category(s): Therapeutics
Anti-malarial drugs targeting PfGARP
Overview Plasmodium falciparum malaria is a leading cause of morbidity and mortality in developing countries, infecting hundreds of millions of individuals and killing more than 300,000 children each year. Certain parasite strains are resistant to all anti-malarial drugs, and the anti-malarial drug discovery pipeline is alarmingly limited. We have...
Published: 11/1/2022   |   Inventor(s): Jonathan Kurtis, Andrew Oleinikov, Dipak Raj
Category(s): Therapeutics
Inhibition of FTO with Entacapone to Treat Glioblastoma
Overview Glioblastoma is one of the most aggressive and lethal human tumors. We are investigating the use of an FDA-approved drug, Entacapone, to treat glioma tumors. Market Opportunity Glioblastoma, one of the most aggressive forms of cancer, has a survival rate of only 14–15 months after diagnosis. There is an urgent need for effective therapies...
Published: 10/15/2022   |   Inventor(s): Nikolaos (Nikos) Tapinos, John Zepecki, David Karambizi
Category(s): Oncology, Therapeutics
New use of CsA-type drugs for the prevention and treatment of neurodegenerative disorders, including Alzheimer’s disease
­Novel Method Repurposes CsA-Type Compounds to Treat Neurodegenerative Disease Overview Alzheimer’s disease remains a challenging disorder for drug development, with many candidate drugs failing clinical trials. Our novel method repurposes camphorsulfonic acid (CsA)-type compounds to treat early-stage Alzheimer’s disease, as well as...
Published: 4/29/2022   |   Inventor(s): Robbert Creton
Category(s): Therapeutics, Neurodegenerative Disease
Small molecule CB002 and its analogs restore the p53 pathway and target an S-phase checkpoint
­Novel Class of Small Molecules Restores Important p53 Pathway Overview Approximately 50% of human cancers involve mutations in the tumor-suppressor gene p53, while the other 50% involve some type of inactivation on the p53 pathway. We have discovered a class of small molecules that restore the p53 pathway, as well as perturb an S-phase checkpoint. ...
Published: 2/22/2022   |   Inventor(s): Wafik El-Deiry, Liz Borrero
Category(s): Therapeutics, Oncology
1 2 3 
© 2024. All Rights Reserved. Powered by Inteum